Clinical Trial Update: The Efficacy and Safety of Pegylated Liposomal Doxorubicin Compared With Capecitabine as First Line Chemotherapy for Metastatic Breast Cancer (P04445/MK-2746-071) [Phase 3]

View source ↗

Summary

Phase 3 trial comparing pegylated liposomal doxorubicin with capecitabine as first-line therapy for metastatic breast cancer has completed and results were post…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Capecitabine (capecitabine)
• Pegylated liposomal doxorubicin (pegylated liposomal doxorubicin)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Breast Cancer | Phase 3 | Status: COMPLETED | Results posted: 2011-11-16